Profit

Lupin Arm Gets US Regulator's Tentative Nod For Anti-Bacterial Drug

 Share
EMAIL
PRINT
COMMENTS
Lupin Arm Gets US Regulator's Tentative Nod For Anti-Bacterial Drug
New Delhi: Drug firm Lupin on Thursday said US-based subsidiary Gavis Pharmaceuticals has received tentative approval from the US Food and Drug Administration (FDA) an anti-bacterial drug in the American market.

Gavis has received tentative approval "for its Azithromycin for oral suspension USP" from the US drug regulator (FDA), Lupin said in a filing to the BSE.

The company's product is a generic version of Pfizer Inc's Zithromax and is indicated for mild to moderate infections caused by bacteria.

Comments
As per IMS MAT sales data, Zithromax Oral Suspension had US sales of $110.6 million.

Shares in Lupin, on Thursday, ended 1.21 per cent higher at Rs 1,501.60 on the BSE, whose benchmark Sensex index finished down 0.10 per cent.

NDTV Beeps - your daily newsletter

................................ Advertisement ................................

................................ Advertisement ................................